On January 6, Sanofi announced that the Class 1 new drug Plozasiran Sodium Injection had been approved in China. On top of dietary control, it is indicated to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). The product had previously been included in priority review and designated a breakthrough therapy.
Following this approval, plozasiran becomes the first approved effective medicine for FCS in China.
Plozasiran (development code: VSA001) is a first-in-class liver-targeted small interfering RNA (siRNA) drug administered once every three months. By efficiently and durably silencing apolipoprotein C-III (APOC3) mRNA, it reduces APOC3 protein expression and thereby lowers serum triglycerides, triglyceride-rich lipoproteins, and their remnant particles.
The drug was originally developed by Arrowhead. In April 2022, Arrowhead announced the establishment of the joint venture Visirna Therapeutics with Vivo Capital to expand innovative drug business in Greater China. Visirna obtained exclusive rights in Greater China to develop and commercialize four investigational RNAi therapies for cardiovascular and metabolic diseases, including plozasiran.
In August 2025, Sanofi obtained Greater China rights to plozasiran for an upfront payment of US$130 million and up to US$265 million in additional milestones, making it an important part of Sanofi’s cardiovascular strategy in China.
The Chinese approval of plozasiran was mainly supported by positive results from several overseas studies, including the pivotal Phase III PALISADE trial in adults with FCS, as well as a Chinese Phase I study.
The PALISADE study (NCT05089084) was a randomized, double-blind, placebo-controlled Phase III trial enrolling 75 participants across 18 countries. Patients were randomized to receive subcutaneous plozasiran 25 mg (n=26), 50 mg (n=24), or placebo (n=25) for 12 months. Those completing the randomized period were eligible to continue into an extension study.
The primary endpoint of PALISADE was placebo-adjusted median percent change in triglyceride level at month 10. Patients treated with plozasiran 25 mg or 50 mg achieved median triglyceride reductions of 80% and 78%, respectively. In addition to meeting the primary endpoint, the trial met all key secondary endpoints.
Across the study period, plozasiran provided sustained triglyceride lowering with low variability and showed a favorable safety profile.
In March 2025, Visirna announced positive topline data from a Chinese Phase III trial of plozasiran in patients with FCS (CTR20231418/NCT05902598), which met the primary efficacy endpoint and all key secondary endpoints.
This randomized, double-blind, placebo-controlled, multicenter Phase III study enrolled 37 patients with FCS who were randomized to receive subcutaneous VSA001 25 mg, 50 mg, or placebo once every three months for 12 months, in order to evaluate efficacy and safety in Chinese adults with FCS. The primary endpoint was the median percent change from baseline in fasting serum triglycerides at month 10 versus placebo.
Data showed that at month 10, fasting serum triglycerides were reduced from baseline by 86% and 89% in the 25 mg and 50 mg groups, respectively. At month 12, reductions were 72% and 79%, respectively. In the VSA001 25 mg group, 90% of patients achieved fasting triglycerides below 500 mg/dL at month 10. Serum APOC3 median levels fell by 93% and 92% at month 10 in the 25 mg and 50 mg groups, respectively.
According to the Insight database, the drug is also being developed for severe hypertriglyceridemia and mixed hyperlipidemia, among other indications, and the program in severe hypertriglyceridemia has already advanced to Phase III. Overseas, the FDA approved the new drug application for plozasiran in November 2024 as an adjunct to diet to reduce triglycerides in adults with FCS.
At present, besides plozasiran, six other siRNA programs against the same target are in development globally. Among them, Hengrui’s HRS-7249 and RiboBio’s SR044 have progressed the furthest, both entering Phase II clinical trials.
FCS is a severe and ultra-rare inherited disease usually caused by various monogenic loss-of-function mutations. It typically leads to extremely elevated fasting triglycerides above 880 mg/dL. Severe triglyceride elevation can result in multiple clinical disorders and serious complications, including atherosclerosis, acute pancreatitis, type 2 diabetes, and hepatic steatosis.
Treatment options for FCS remain limited and do not adequately meet patient needs. As the first approved therapy of its kind in China, plozasiran offers patients a highly competitive new treatment choice.